#### **CLAIM AMENDMENTS**

B1

1. (currently amended)

A recombinant Recombinant antibody recognizing IOR C2

antigen, the recombinant antibody being produced and single chain Fv fragment derived from murine monoclonal antibody IOR C5 produced by the hybridoma deposited with the European Collection of Cell Cultures under accession number ECCC 97061101, wherein said recombinant antibody comprises has the Complementary Determining Regions (CDRs) CDRs and framework regions (FRs) of the murine monoclonal antibody IOR C5 and humanized human constant regions in its for light and heavy chains, wherein the heavy and light chains comprise at least one framework region point mutation for reducing its immunogenicity.

### 2.-4. (cancelled)

5. (currently amended, previously once amended) The recombinant Humanised antibody according to claim 1, wherein the framework region point mutation is selected from the group consisting of: 4 which has in the framework regions of the heavy and light chains any of the following point mutations

**HEAVY CHAIN:** 

Position 10 ASP for GLY

Position 17 SER for THR

Position 43 ASN for LYS

# Position 44 LYS for GLY

LIGHT CHAIN:

Position 15 ILE for LEU

Position 45 LYS for ARG

Position 63 THR for SER

- 6. (cancelled)
- 7. (currently amended) Cellular line expressing the recombinant antibody of any of claims 1 or to 5.
- 8. (currently amended) Host cell which expresses express the single chain Fv fragment of claims 16 or 17 1 and 6.
- 9. (currently amended) Pharmaceutical composition for treating recto and colon malignant tumors tumours, metastasis thereof and recurrences, comprising the recombinant antibody of any of claims 1 or to 5 and a suitable excipient.
- 10. (currently amended) Pharmaceutical composition for treating recto and colon malignant tumors tumours, metastasis thereof and recurrences, comprising the single chain Fv fragment of claims 16 or 17 1 and 6 and a suitable excipient.

- 11. (currently amended) Pharmaceutical composition for <u>localization</u> <del>localisation</del> and identification "*in vivo*" of recto and colon malignant <u>tumors</u> <del>tumours</del>, metastasis thereof and recurrences, comprising the recombinant antibody of <del>any of</del> claims 1 <u>or</u> to 5.
- 12. (currently amended) Pharmaceutical composition for <u>localization</u> localisation and identification "*in vivo*" of recto and colon malignant <u>tumors</u> tumours, metastasis thereof and recurrences, comprising the single chain Fv fragment of claims <u>16 or 17 1 and 6</u>.
- 13. (currently amended) Pharmaceutical composition according to claims 9 or 11 to 12 comprising also compounds for radiolabeling the these antibodies of fragments, which are mixed to produce an aqueous administrable solution.
- 14. (currently amended) Pharmaceutical composition according to claim 13 comprising technetium tecnecium 99, rhenium rhenio 186, rhenium rhenio 188 or analogues as radiolabelers radiolabellers.

# 15. (cancelled)

16. (new) A single chain Fv fragment recognizing IOR C2 antigen, the Fv fragment being produced from murine monoclonal antibody IOR C5 produced by the hybridoma deposited with the European Collection of Cell Cultures under accession number 97061101, said Fv fragment containing the Complementary Determining Regions (CDRs) and frameworks regions (FRs) of the murine monoclonal antibody IOR C5 and

humanized constant regions in its heavy and light chains, wherein the heavy and light chains comprise at least one framework region point mutation for reducing its immunogenicity.

17. (new) The single chain Fv fragment according to claim 16, wherein the framework region point mutation is selected from the group consisting of:

## **HEAVY CHAIN:**

Position 10 ASP by GLY

Position 17 SER by THR

Position 43 ASN by LYS

Position 44 LYS by GLY

## **LIGHT CHAIN:**

Position 15 ILE by LEU

Position 45 LYS by ARG

Position 63 THR by SER

- 18. (new) Pharmaceutical composition according to claims 10 or 12 further comprising compounds for radiolabeling the Fv fragments.
- 19. (new) Pharmaceutical composition according to claim 18 comprising technetium99, rhenium 186, rhenium 188 or analogues as radiolabelers.



•

) (\*\*) (\*\*) .